Full history for every metric is available with a Kvantra account
Filament Health Corp. (FH.NE)
Key financial summary
Financials in CAD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | - | 0 | 0 | 0 | 2 | 1 | 0 |
| Operating profit | CAD m | -4 | -3 | |||||
| Net profit | CAD m | - | -0 | -9 | -16 | -5 | -5 | -4 |
| EPS reported | CAD | -0.02 | -0.02 | |||||
| Operating cashflow per share | CAD | -0.01 | -0.00 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.01 | -0.00 | |||||
| Free cash flow | CAD m | -2 | -1 | |||||
| Net debt | CAD m | -0 | -0 | |||||
| Book value equity | CAD m | 2 | 1 | |||||
| Book value per share | CAD | 0.01 | 0.00 | |||||
| Number of shares | m | 237.38 | 261.79 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.08 | 3.67 | |||||
| P/S LTM | x | 11.55 | 8.39 | |||||
| P/FCF LTM | x | -3.04 | -2.68 | |||||
| EV/EBITDA LTM | x | -1.55 | -0.86 | |||||
| EV/Sales LTM | x | 11.34 | 7.56 | |||||
| Earnings Yield LTM | % | -69.79% | -53.82% | |||||
| FCF Yield | % | -32.85% | -37.25% | |||||
| Quality | ||||||||
| ROE | % | -284.45% | -137.85% | |||||
| ROIC | % | -174.24% | -73.75% | |||||
| Operating margin | % | -594.96% | -448.70% | |||||
| Gross margin | % | 65.12% | 100.00% | |||||
| FCF/Sales | % | -379.36% | -229.13% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -71.06% | -81.10% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -8.84 | -3.06 | |||||
| Net Debt/EBITDA | x | 0.03 | 0.17 | |||||
| EBIT/Net interest | x | -15.36 | -184.62 | |||||
| Net debt/market cap | % | -5.49% | -9.88% | |||||
| Net debt/Equity | x | -0.22 | -0.36 | |||||
| Gross debt/equity | x | 0.15 | 0.45 | |||||
Company overview
Filament Health Corp. focuses on the discovery and advanced extraction of natural psychedelic compounds. The firm actively cultivates psychedelic flora, conducts genetic investigations, develops extraction methodologies, and performs internal clinical trials. It then supplies its intellectual property and potential pharmaceutical agents to drug developers, scientific researchers, and other authorized organizations. Its corporate headquarters are located in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Filament Health Corp. (FH.NE)
Filament Health Corp. focuses on the discovery and advanced extraction of natural psychedelic compounds. The firm actively cultivates psychedelic flora, conducts genetic investigations, develops extraction methodologies, and performs internal clinical trials. It then supplies its intellectual property and potential pharmaceutical agents to drug developers, scientific researchers, and other authorized organizations. Its corporate headquarters are located in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free